Univariate and Multivariate Analyses Identifying Determinants of the BUMP Score
| Parameter | Nonmetastatic (total n = 260) | Metastatic (total n = 188) | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|---|---|
| OR | P | OR | P | |||
| Clinical setting | ||||||
| Primary staging | 167 (65.5) | 88 (34.5) | 1.00 (Ref) | |||
| Restaging | 93 (48.2) | 100 (51.8) | 2.04 (1.18–3.52) | 0.010 | — | NS |
| Initial PSA (ng/mL) | 8.7 (6.0–16.5) | 14.0 (7.7–33.0) | 1.48 (1.16–1.88) | 0.001 | — | NS |
| ISUP grade group | ||||||
| 1 | 17 (68.0) | 8 (32.0) | 1.00 (Ref) | |||
| 2 | 77 (77.8) | 22 (22.2) | 0.61 (0.18–2.08) | |||
| 3 | 70 (61.4) | 44 (38.6) | 1.34 (0.41–4.32) | |||
| 4 | 53 (47.3) | 59 (52.7) | 2.37 (0.71–7.92) | |||
| 5 | 31 (47.0) | 35 (53.0) | 2.40 (0.70–8.26) | 0.009 | — | NS |
| Missing | 12 (37.5) | 20 (62.5) | — | — | ||
| PSA at PET/CT (ng/mL) | 6.2 (1.1–13.0) | 6.8 (3.0–27.0) | 1.19 (1.02–1.38) | 0.027 | — | NS |
| ADT at PET/CT | ||||||
| No | 230 (67.1) | 113 (32.9) | 1.00 (Ref) | 1.00 (Ref) | ||
| Yes | 30 (28.8) | 74 (71.2) | 5.02 (2.62–9.63) | <0.001 | 4.06 (1.91–8.67) | <0.001 |
| Unknown | 0 (0) | 1 (100) | — | — | ||
| PSMA injected dose (MBq) | 309.0 (277.0–339.5) | 312.0 (281.0–343.0) | 1.03 (0.98–1.08) | 0.277 | ||
| Uptake time (min) | 96.0 (90.0–116.0) | 95.0 (90.0–117.0) | 1.01 (0.88–1.16) | 0.902 | ||
| Bone uptake site | ||||||
| Ribs | 104 (71.7) | 41 (28.3) | 1.00 (Ref) | |||
| Spine | 70 (58.3) | 50 (41.7) | 1.81 (1.19–2.76) | |||
| Pelvis | 66 (50.0) | 66 (50.0) | 2.54 (1.61–3.99) | |||
| Other sites | 20 (39.2) | 31 (60.8) | 3.93 (1.96–7.89) | <0.001 | — | NS |
| HUmean | 180.6 (118.3–247.0) | 211.4 (150.9–320.5) | 1.03 (1.01–1.05) | 0.001 | 1.04 (1.02–1.06) | <0.001 |
| HUmax | 592.0 (420.0–790.0) | 744.5 (541.0–926.0) | 1.02 (1.01–1.02) | <0.001 | — | NS |
| SUVmax | 4.5 (3.7–5.6) | 10.2 (5.2–21.9) | 1.35 (1.25–1.46) | <0.001 | 1.39 (1.27–1.52) | <0.001 |
| PSMA visual score | 1.0 (1.0–1.0) | 2.0 (1.0–3.0) | 2.38 (1.79–3.17) | <0.001 | — | NS |
| PSMA-TV (mL)* | 1.8 (1.1–3.0) | 1.8 (0.9–3.7) | 1.00 (0.96–1.05) | 0.947 | ||
| TL-PSMA* | 5.0 (3.4–9.2) | 11.1 (5.0–30.0) | 1.02 (1.01–1.04) | 0.012 | — | NS |
↵* Variables were evaluated independently in multivariate analysis to avoid collinearity instability.
OR = odds ratio; Ref = reference value; NS = not significant; PSA = prostate-specific antigen; ISUP = International Society of Urological Pathology; PSMA-TV = PSMA tumor volume; TL-PSMA = total lesion PSMA.
Qualitative data are number and percentage. Continuous data are median and interquartile range. OR data are number and 95% CI in parentheses.